Targeting the MLL complex in castration resistant prostate cancer

Resistance to androgen deprivation therapies and increased androgen receptor (AR) activity are major drivers of castration resistant prostate cancer (CRPC). Although prior work focused on targeting AR directly, co-activators of AR signaling—which may represent new therapeutic targets—are relatively...

Descripción completa

Detalles Bibliográficos
Autores principales: Malik, Rohit, Khan, Amjad P., Asangani, Irfan A., Cieślik, Marcin, Prensner, John R., Wang, Xiaoju, Iyer, Matthew K., Jiang, Xia, Borkin, Dmitry, Escara-Wilke, June, Stender, Rachell, Wu, Yi-Mi, Niknafs, Yashar S., Jing, Xiaojun, Qiao, Yuanyuan, Palanisamy, Nallasivam, Kunju, Lakshmi P., Krishnamurthy, Pranathi M., Yocum, Anastasia K., Mellacheruvu, Dattatreya, Nesvizhskii, Alexey I., Cao, Xuhong, Dhanasekaran, Saravana M., Feng, Felix Y., Grembecka, Jolanta, Cierpicki, Tomasz, Chinnaiyan, Arul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390530/
https://www.ncbi.nlm.nih.gov/pubmed/25822367
http://dx.doi.org/10.1038/nm.3830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390530/
https://www.ncbi.nlm.nih.gov/pubmed/25822367
http://dx.doi.org/10.1038/nm.3830

Ejemplares similares